Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.
about
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials.A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors.
P2860
Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Dovitinib and erlotinib in pat ...... ncer: A drug-drug interaction.
@ast
Dovitinib and erlotinib in pat ...... ncer: A drug-drug interaction.
@en
type
label
Dovitinib and erlotinib in pat ...... ncer: A drug-drug interaction.
@ast
Dovitinib and erlotinib in pat ...... ncer: A drug-drug interaction.
@en
prefLabel
Dovitinib and erlotinib in pat ...... ncer: A drug-drug interaction.
@ast
Dovitinib and erlotinib in pat ...... ncer: A drug-drug interaction.
@en
P2093
P2860
P1433
P1476
Dovitinib and erlotinib in pat ...... ncer: A drug-drug interaction.
@en
P2093
Adam Frymoyer
Heather A Wakelee
Joel W Neal
Jonathan W Riess
Millie Das
Sukhmani K Padda
P2860
P304
P356
10.1016/J.LUNGCAN.2015.06.011
P577
2015-06-22T00:00:00Z